IL2 and melanoma: The authors showed that ABCB5+MHC class II+ cells displayed higher capacity than ABCB5- MHC class II-negative melanoma cells to inhibit IL-2-dependent T-cell activation and support the induction of CD4+CD25+FoxP3+ regulatory T cells.